Article citationsMore>>

S. J. Hadziyannis, H. Sette, T. R. Morgan, V. Balan, M. Diago, P. Marcellin, G. Ramadori, H. Bodenheimer, D. Bernstein, M. Rizzetto, S. Zeuzem, P. J. Pockros, A. Lin and A. M. Ackrill, “Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C: A Randomized Study of Treatment Duration and Ribavirin Dose,” Annals of Internal Medicine, Vol. 140, No. 5, 2004, pp. 346-355.

has been cited by the following article:

• TITLE: Identification of HCV Inhibitors from a Cell-Based Sub-Genomic Replicon Screen

  AUTHORS: David C. Pryde, Thien-Duc Tran, Mark Gardner, Chris Pickford, Stephen M. Shaw, Mike Westby, Tanya Parkinson, Caroline Smith-Burchnell, Rob Webster, Satish Dayal

  KEYWORDS: HCV; Replicon; Antiviral; Cell-Based Screen

  JOURNAL NAME: Open Journal of Medicinal Chemistry, Vol.3 No.1, March 29, 2013

  ABSTRACT: A high throughput screen of the Pfizer compound collection was carried out using a hepatitis C virus (HCV) genotype 1b subgenomic replicon cell line. Those confirmed hits that demonstrated broad spectrum activity without overt cytotoxicity were further evaluated, leading to the identification of a series of pyrrolopyridines with excellent antiviral activity in a fully infectious HCV cell-based assay and pharmacokinetic properties.